Drug Trial Radar · NCT03004417
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
Last checked: Nov 19, 2026Latest source record: Jul 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Oct 31, 2016
Primary completion
Dec 28, 2017
Study completion Dec 28, 2017
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- SGS S.A.
- First posted
- Dec 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Effect of CHF 6001 on biomarkers of inflammation in induced sputum and in blood, on pulmonary function and on symptoms benefits in comparison with placebo.
Conditions
- COPD
Interventions
CHF 6001 Dose1Drug
CHF 6001 plus placebo
CHF 6001 Dose2Drug
CHF 6001 only (high dose)
PlaceboOther
Placebo only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sputum biomarkersTime frame: Change from baseline to end of treatment (mean Day 20, 26 and 32 values) at each period;
- Sputum biomarkersTime frame: Predose and end of treatment at Day 32 of each period
- Sputum cell countTime frame: Change from baseline to end of treatment (mean Day 20, 26 and 32 values) at each period;
- Blood BiomarkersTime frame: Change from baseline to Day 32 of each period;
- Blood BiomarkersTime frame: Predose and end of treatment at Day 32 of each period
- Lung function: SpirometryTime frame: Change from baseline to Day 20 Day 26 and 32 of each period
- Lung function: OscillometryTime frame: Change from baseline to Day 32 of each period
- PK: AUC0-12h,ssTime frame: on Day 32 (steady state) of each period.
- PK: CmaxTime frame: on Day 32 (steady state) of each period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicines Evaluation Unit Ltd
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.